PRME Prime Medicine, Inc.
Prime Medicine, Inc. (PRME) is expected to report earnings on November 5, 2026, after the market close. The consensus earnings estimate is a loss of $0.23 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.0% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Prime Medicine, Inc.
Prime Medicine Inc. is a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies. Prime Medicine Inc. is based in CAMBRIDGE, Mass.
Sector
Healthcare
Industry
Biotechnology